July 25, 2025 – The thematic forum on "CNS Drug Development", an important component of the "T20+ Conference", was successfully held on the shores of Suzhou's Jinji Lake.
The forum brought together numerous experts and scholars from academia and industry to engage in in-depth discussions on CNS drug R&D strategies, novel target discovery, clinical translation, and the driving role of new technologies. The goal was to foster innovation and collaboration in the field of neuroscience and identify effective strategies to overcome challenges in CNS drug development.
The forum was co-chaired by Dr. Guo Fei, Founder of Kylin Lab, and Mr. Yuan Dawei, Chairman of Quark Medicine.
Presentations: Diverse and Insightful
The forum focused on the clinical needs, R&D hotspots, and strategic planning of CNS drugs, analyzed the mechanisms of action of novel targets, discussed core issues and solutions in innovative drug development, and facilitated extensive exchanges on how to accelerate innovation and clinical translation through collaboration.
It covered a wide range of CNS diseases, including Alzheimer's disease, ADHD, neurocritical conditions, Parkinson's disease, pain, ALS, depression, stroke, and sleep disorders, and involved mainstream drug R&D modalities such as small molecules, small nucleic acids, antibodies, and cell therapies.
Roundtable Dialogue: Analyzing Challenges, Exploring Pathways
Panelists shared insights based on their respective companies’ contexts, discussing different considerations in CNS pipeline, exchanging views on drug formulations and delivery methods capable of crossing the blood-brain barrier for effective administration, and envisioning the significant potential of key technologies like organoid models and AI in advancing brain science.
They also emphasized the importance of basic research and expressed great anticipation and confidence in the development of China's CNS field.
Swipe left or right for more event photos
The forum attracted numerous industry peers, resulting in a fully occupied and exceptionally lively venue. The intense heat of Suzhou in July, with steam rising from Jinji Lake, mirrored the fervent exchange of ideas inside the conference hall!
This forum brought together diverse strengths in the field of CNS drug R&D, injecting new vitality into the development of novel CNS therapeutics. It is hoped that through the collective efforts of the industry, more breakthroughs will be achieved in CNS drug R&D, bringing hope to patients.
Boundless Exchange, Ideas Continue to Ignite
Beyond the formal sessions, sparks of ideas continued to fly.
The Kylin Lab exhibition booth became a hotspot for interaction, attracting many attendees to stop, discuss, and exchange ideas.
Kylin Lab specializes in preclinical services for CNS drug R&D, boasting 70+ disease models, 100+ evaluation paradigms, and 5 major R&D platforms, having served over 100 clients.
About Kylin Lab
CNSxplore | Pioneering CNS Drug Discovery--In vitro and in vivo, Beyond limits
Kylin Lab is a preclinical CRO company specializing in central nervous system (CNS) diseases, dedicated to offering one stop solutions for CNS drug discovery. With a portfolio of fully-validated cellular and animal disease models, combined with comprehensive research and analytical capabilities, we empower clients to accelerate the development of innovative therapies and reduce clinical trial risks.
Kylin Lab boasts an experienced technical team well-versed in international regulations, along with high-standard experimental platforms. Our core technologies include AI-driven phenotypic screening, humanized stem cells and organoids, electrophysiology, high-throughput electroencephalography (EEG), histology, and molecular biology. Our expertise spans a broad range of areas including Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, spinal muscular atrophy (SMA), pain, and stroke etc.
Since its establishment, Kylin Lab has adhered to the philosophy of “Pioneering R&D, Leading in technology Quality-first, Customer-centric.” We have served hundreds of clients, successfully completed numerous thematic research projects and IND submissions, and established a high-quality, stable, and forward-looking efficacy evaluation system.
